Medications and the risk of perforated appendicitis: an adverse event report system (FAERS) database analysis
CONCLUSION: Findings from the FAERS database highlight the risk of appendiceal perforation in the context of different classes of drugs. Larger pharmacovigilance studies are needed to confirm these observations as well as overcome inherent reporting biases.PMID:36322707 | DOI:10.1080/17474124.2022.2143346 (Source: Expert Review of Gastroenterology and Hepatology)
Source: Expert Review of Gastroenterology and Hepatology - November 2, 2022 Category: Gastroenterology Authors: Daryl Ramai Daniel Mozell Antonio Facciorusso Anjali Kewalramani Saurabh Chandan Banreet Dhindsa Amaninder Dhaliwal Shahab Khan Douglas G Adler Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
